{"filing":{"accession_number":"0001664710-26-000056","cik":"0001664710","ticker":"KROS","company_name":"Keros Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"kros-20260928.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000056/kros-20260928.htm"},"events":[{"id":35315,"run_id":32523,"accession_number":"0001664710-26-000056","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces the first patient dosing in a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy, a material clinical development milestone for a clinical-stage biopharmaceutical company. This represents significant operational progress in advancing the company's lead product candidate and clinical pipeline, with initial data expected in H1 2027. While this is a clinical milestone rather than a financial event, earnings release, or governance matter, it constitutes a material operational event that would affect a reasonable investor's assessment of the company's progress and pipeline advancement.","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39329,"accession_number":"0001664710-26-000056","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the first patient dosing in a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy, a material clinical development milestone for a clinical-stage biopharmaceutical company. This represents significant operational progress in advancing the company's lead product candidate and clinical pipeline, with initial data expected in H1 2027. While this is a clinical milestone rather than a financial event, earnings release, or governance matter, it constitutes a material operational event that would affect a reasonable investor's assessment of the company's progress and pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:06:39.253978+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39329,"accession_number":"0001664710-26-000056","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces the first patient dosing in a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy, a material clinical development milestone for a clinical-stage biopharmaceutical company. This represents significant operational progress in advancing the company's lead product candidate and clinical pipeline, with initial data expected in H1 2027. While this is a clinical milestone rather than a financial event, earnings release, or governance matter, it constitutes a material operational event that would affect a reasonable investor's assessment of the company's progress and pipeline advancement.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:06:39.253978+00:00","company_name":"Keros Therapeutics, Inc.","ticker":"KROS","filing_date":"2026-09-28"}]}